AGNPF - Algernon Pharmaceuticals Inc.

QQQ $ 452.83 $ 6.97 (1.56 %)

DIA $ 399.31 $ 3.70 (0.94 %)

SPY $ 529.09 $ 6.48 (1.24 %)

TLT $ 92.14 $ 1.24 (1.36 %)

GLD $ 220.89 $ 2.80 (1.28 %)

Previous Close

$ 0.09924

Open

Bid

-- x --

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 0.04 - $ 0.20

Volume

530

Average Volume

Market Cap

Beta (5Y Monthly)

$ 0.60

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

psyched-dea-revisits-ban-on-two-psychedelics-farewell-russell-newcombe-podcast-episode-on-kanna--more

Psyched: DEA Revisits Ban On Two Psychedel...
04/17/2024 12:42:33

dmt-for-stroke-treatment-algernon-sets-phase-2-clinical-trial-design

DMT For Stroke Treatment: Algernon Sets Ph...
04/03/2024 20:45:29

psyched-professional-practice-guidelines-dmt-for-stroke-dua-lipa--amanda-feilding-clinical-results--more

Psyched: Professional Practice Guidelines,...
08/14/2023 13:46:56

First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published

dmt-as-a-treatment-for-stroke-this-company-is-closer-to-launching-its-phase-2-study

DMT As A Treatment For Stroke? This Compan...
08/08/2023 15:00:33

Algernon NeuroScience (AGN Neuro), a subsidiary of Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) (CSE:AGN) (FRANKFURT:AGW0), has...

dmts-clinical-path-for-treating-tbi-and-stroke-phase-1-dosing-finished-as-phase-2-gears-up

DMT's Clinical Path For Treating TBI And S...
06/05/2023 17:56:33

Algernon Pharmaceuticals’ (OTCQB: AGNPF) wholly-owned Algernon NeuroScience (AGN Neuro) successfully completed dosing the third...

how-to-finance-a-psychedelics-business-learn-from-these-four-companies

How To Finance A Psychedelics Business? Le...
04/04/2023 20:41:42

Clearmind Medicine Announces Pricing of $3.5 Million Public Offering

intravenous-dmt-therapy-seeks-ideal-dosage-for-stroke-and-tbi-treatment

Intravenous DMT Therapy Seeks Ideal Dosage...
04/04/2023 18:25:08

Canadian biopharma company Algernon Pharmaceuticals Inc.

psyched-9-us-reform-bills-ayahuasca-a-release-for-prince-harry-at-home-therapy--more

Psyched: 9 US Reform Bills, Ayahuasca 'A R...
03/07/2023 15:29:18

Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization ...

algernon-pharmaceuticals-ap-188-dmt-compound-shows-promise-for-the-treatment-of-tbi

Algernon Pharmaceuticals AP-188 DMT Compou...
03/03/2023 14:48:51

In this new podcast, TDR Founder Shadd Dales interviewed Algernon Pharmaceuticals (OTC: AGNPF) CEO, Christopher Moreau.

algernon-pharmaceuticals-goes-41-in-forward-share-split-after-announcing-new-tbi-program

Algernon Pharmaceuticals Goes 4:1 In Forwa...
03/02/2023 02:30:45

Canadian clinical-stage psychedelics developer Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) will start trading its Class A comm...

psyched-hawaii-and-minnesotas-bills-studying-2c-b-vs-psilocybin-filament-ceo-plus-brock-pierce-and-jeremy-gardner-discuss-the-industrys-future-and-more

Psyched: Hawaii And Minnesota's Bills, Stu...
02/28/2023 00:28:58

Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair o...

psyched-four-new-states-with-reform-bills-psilocybin-for-genetic-disorders-and-functional-neurological-disorder-struggle-for-access--more

Psyched: Four New States With Reform Bills...
02/21/2023 22:19:00

Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, N...

developing-psychedelic-treatments-for-traumatic-brain-injury-algernon-launches-new-program

Developing Psychedelic Treatments For Trau...
02/21/2023 18:00:42

Biopharma company Algernon Pharmaceuticals (OTCQB: AGNPF) has launched a new clinical research program via a subsidiary.

algernon-touts-positive-study-findings-confirms-next-trial-phase-with-escalated-dose

Algernon Touts Positive Study Findings, Co...
02/16/2023 18:38:00

Algernon Pharmaceuticals (OTCQB: AGNPF)’s subsidiary Algernon NeuroScience has completed the first cohort in its Phase 1 clinic...

a-psychedelic-program-for-treatment-of-stroke-new-clinical-trial-begins-dosing

A Psychedelic Program For Treatment Of Str...
01/18/2023 20:37:58

Canadian clinical-stage psychedelics company Algernon Pharmaceuticals (OTCQB: AGNPF)’s newly created subsidiary Algernon NeuroS...

psychedelic-subsidiaries-news-blackhawk-spins-out-three-companies-algernon-creates-a-new-one

Psychedelic Subsidiaries News: Blackhawk S...
01/03/2023 18:54:43

The psychedelics space is up and running. Together with the start of the new year, two companies have shared their latest finan...

psyched-musks-empathy-tweets-psychedelics-in-congress-oregons-opt-outs-maps-mdma-trial-and-more

Psyched: Musk's Empathy Tweets, Psychedeli...
11/22/2022 00:13:49

Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy

psychedelic-therapeutics-for-human-stroke-participant-screening-expects-to-begin-soon

Psychedelic Therapeutics For Human Stroke:...
11/16/2022 17:47:40

Canadian clinical-stage psychedelics company Algernon Pharmaceuticals Inc.

tackling-depression-with-psychedelics-new-phase-2-clinical-study-begins-at-yale-university

Tackling Depression With Psychedelics: New...
10/24/2022 16:27:04

Canadian-based psychedelics biopharma company Algernon Pharmaceuticals Inc.

a-foundational-study-on-stroke-is-ready-here-is-why-its-important

A Foundational Study On Stroke Is Ready. H...
09/12/2022 18:26:42

Biopharma company Algernon Pharmaceuticals Inc's (OTC: AGNPF) recently announced plan for a Phase 1 clinical study on DMT f...